Effects of Multiple Baricitinib (LY3009104) Doses on the Pharmacokinetics of a Cytochrome P450 3A Substrate, Simvastatin, in Healthy Subjects

Trial Profile

Effects of Multiple Baricitinib (LY3009104) Doses on the Pharmacokinetics of a Cytochrome P450 3A Substrate, Simvastatin, in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Baricitinib (Primary) ; Simvastatin
  • Indications Cystic fibrosis; Diabetic cardiomyopathy; Diabetic nephropathies; Hypercholesterolaemia; Low HDL cholesterol; Psoriasis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Jan 2014 Status changed from no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top